GlyTherix Ltd. is a targeted radiotherapy company with a clinical-stage product showing an excellent safety profile in high unmet-need cancers. Our antibody, Miltuximab, specifically targets GPC-1, a protein found on solid tumors such as prostate, bladder, pancreatic, glioblastoma, oesophageal, and ovarian cancers, and is not present in healthy tissue. The company has a solid proprietary and intellectual property position covering the Miltuximab antibody, epitope, and antigen. This provides robust and long-term protection for commercializing critical new treatments to people with little hope.